Xenon Financial Statements From 2010 to 2025
| XENE Stock | USD 40.47 0.28 0.70% |
Check Xenon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Xenon Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Xenon financial statements analysis is a perfect complement when working with Xenon Pharmaceuticals Valuation or Volatility modules.
Xenon |
Xenon Pharmaceuticals Company Shares Owned By Institutions Analysis
Xenon Pharmaceuticals' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Xenon Pharmaceuticals Shares Owned By Institutions | 99.63 % |
Most of Xenon Pharmaceuticals' fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xenon Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 99% of Xenon Pharmaceuticals are shares owned by institutions. This is 123.19% higher than that of the Biotechnology sector and 109.75% higher than that of the Health Care industry. The shares owned by institutions for all United States stocks is 154.09% lower than that of the firm.
Xenon Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Xenon Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Xenon Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Xenon Pharmaceuticals competition to find correlations between indicators driving Xenon Pharmaceuticals's intrinsic value. More Info.Xenon Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Xenon Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Xenon Pharmaceuticals Financial Statements
Xenon Pharmaceuticals stakeholders use historical fundamental indicators, such as Xenon Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Xenon Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Xenon Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Xenon Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Xenon Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. Xenon Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 149 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Xenon Pharmaceuticals is a strong investment it is important to analyze Xenon Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Xenon Pharmaceuticals' future performance. For an informed investment choice regarding Xenon Stock, refer to the following important reports:Check out the analysis of Xenon Pharmaceuticals Correlation against competitors. For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenon Pharmaceuticals. If investors know Xenon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Xenon Pharmaceuticals is measured differently than its book value, which is the value of Xenon that is recorded on the company's balance sheet. Investors also form their own opinion of Xenon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Xenon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Xenon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.